Avelumab or pembrolizumab: Which is the better subsequent treatment in patients with advanced urothelial carcinoma who did not show progression after 4 cycles of first line chemotherapy?
| Autor: | Tomisaki, Ikko, Harada, Mirii, Minato, Akinori, Higashijima, Katsuyoshi, Takaba, Tomohisa, Nagata, Yujiro, Harada, Kenichi, Fujimoto, Naohiro |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p633-633, 193p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|